

BETNOVATE SCALP APPLICATION

PRESENTATION

BETNOVATE scalp application contains betamethasone 0.1% w/w as betamethasone valerate.

Excipients: Carbomer, Isopropyl alcohol, Sodium hydroxide, Purified water

INDICATIONS

Steroid responsive dermatoses of the scalp, such as psoriasis, seborrhoea capitis, inflammation associated with severe dandruff.

DOSAGE AND ADMINISTRATION

A small quantity of BETNOVATE Scalp Application should be applied to the scalp night and morning until improvement is noticeable. It may then be possible to sustain improvement by applying once a day, or less frequently.

For topical application.

This product is flammable. Keep the liquid away from open fire and flames and all sources of ignition including smoking during application and immediately after use.

Paediatric population

Betamethasone valerate is contraindicated in children under one year of age.

Children are more likely to develop local and systemic side effects of topical corticosteroids and, in general, require shorter courses and less potent agents than adults; therefore, courses should be limited to five days and occlusion should not be used.

Care should be taken when using betamethasone valerate to ensure the amount applied is the minimum that provides therapeutic benefit.

Elderly

Clinical studies have not identified differences in responses between the elderly and younger patients. The greater frequency of decreased hepatic or renal function in the elderly may delay elimination if systemic absorption occurs. Therefore the minimum quantity should be used for the shortest duration to achieve the desired clinical benefit.

Renal / Hepatic Impairment

In case of systemic absorption (when application is over a large surface area for a prolonged period) metabolism and elimination may be delayed therefore increasing the risk of systemic toxicity. Therefore the minimum quantity should be used for the shortest duration to achieve the desired clinical benefit.

CONTRA-INDICATIONS

Hypersensitivity to the active substance or any of the excipients listed.

Infections of the scalp. Dermatoses in children under one year of age, including dermatitis.

WARNINGS AND PRECAUTIONS

BETNOVATE should be used with caution in patients with a history of local hypersensitivity to other corticosteroids. Local hypersensitivity reactions (see *Adverse Reactions*) may resemble symptoms of the condition under treatment.

Manifestations of hypercortisolism (Cushing's syndrome) and reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, leading to glucocorticosteroid insufficiency, can occur in some individuals as a result of increased systemic absorption of topical steroids. If either of the above are observed, withdraw the drug gradually by reducing the frequency of application, or by substituting a less potent corticosteroid. Abrupt withdrawal of treatment may result in glucocorticosteroid insufficiency (see *Adverse Reactions*).

Risk factors for increased systemic effects are:

- Potency and formulation of topical steroid
- Duration of exposure
- Application to a large surface area
- Increasing hydration of the stratum corneum
- Use on occluded areas of the skin
- Use on thin skin areas
- Use on broken skin or other conditions where the skin barrier may be impaired
- In comparison with adults, children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic adverse effects. This is because children have an immature skin barrier and a greater surface area to body weight ratio compared with adults.

Paediatric population

In infants and children under 12 years of age, treatment courses should be limited to five days and occlusion should not be used; long-term continuous topical corticosteroid therapy should be avoided where possible, as adrenal suppression can occur.

Infection risk with occlusion

Bacterial infection is encouraged by the warm, moist condition within skin folds or caused by occlusive dressings. When using occlusive dressings, the skin should be cleansed before a fresh dressing is applied.

Use in Psoriasis

Topical administration should be used with caution in psoriasis as rebound relapses, development of tolerances, risk of generalised pustular psoriasis and development of local or systemic toxicity due to impaired barrier function of the skin have been reported in some cases. If used in psoriasis careful patient supervision is important.

Visual disturbance

Visual disturbance may be reported with systemic and topical corticosteroid use. If a patient presents with symptoms such as blurred vision or other visual disturbances, the patient should be considered for referral to an ophthalmologist for evaluation of possible causes which may include cataract, glaucoma or rare diseases such as central serous chorioretinopathy (CSCR) which have been reported after use of systemic and topical corticosteroids.

Patients should be advised to avoid:

- Keep the preparation away from the eyes
- Avoid smoking whilst applying BETNOVATE scalp application
- Avoid fire, flame and heat including use of hair dryer after application

Interactions

Co-administered drugs that can inhibit CYP3A4 (e.g. ritonavir, itraconazole) have been shown to inhibit the metabolism of corticosteroids leading to increased systemic exposure. The extent to which this interaction is clinically relevant depends on the dose and route of administration of the corticosteroids and the potency of the CYP3A4 inhibitor.

Fertility, Pregnancy and Lactation

Fertility

There are no data in humans to evaluate the effect of topical corticosteroids on fertility.

Pregnancy

There are limited data from the use of betamethasone valerate in pregnant women.

Topical administration of corticosteroids to pregnant animals can cause abnormalities of foetal development (see *Preclinical Safety Data*).

The relevance of this finding to humans has not been established; however, administration of betamethasone valerate during pregnancy should only be considered if the expected benefit to the mother outweighs the risk to the foetus. The minimum quantity should be used for the minimum duration.

Lactation

The safe use of topical corticosteroids during lactation has not been established.

It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable amounts in breast milk. Administration of betamethasone valerate during lactation should only be considered if the expected benefit to the mother outweighs the risk to the infant.

If used during lactation betamethasone valerate should not be applied to the breasts to avoid accidental ingestion by the infant.

Effects on ability to drive and use machines

There have been no studies to investigate the effect of betamethasone valerate on driving performance or the ability to operate machinery. A detrimental effect on such activities would not be anticipated from the adverse reaction profile of topical betamethasone valerate.

Adverse Reactions

Adverse drug reactions (ADRs) are listed below by MedDRA system organ class and by frequency. Frequencies are defined as: very common ($\geq 1/10$), common ($\geq 1/100$ and $< 1/10$), uncommon ($\geq 1/1,000$ and $< 1/100$), rare ($\geq 1/10,000$ and $< 1/1,000$) and very rare ($< 1/10,000$), including isolated reports.

Infections and Infestations

Very rare Opportunistic infection

Immune System Disorders

Very rare Hypersensitivity, generalised rash

Endocrine Disorders

Very rare Hypothalamic-pituitary adrenal (HPA) axis suppression

Cushingoid features (e.g. moon face, central obesity), delayed weight gain/growth retardation in children, osteoporosis, glaucoma, hyperglycaemia/glucosuria, cataract, hypertension, increased weight/obesity, decreased endogenous cortisol levels, alopecia, trichorrhexis

Skin and Subcutaneous Tissue Disorders

Common Pruritus, local skin burning /skin pain

Very rare Allergic contact dermatitis /dermatitis, erythema, rash, urticaria, pustular psoriasis, skin thinning* / skin atrophy*, skin wrinkling*, skin dryness*, striae*, telangiectasias*, pigmentation changes*, hypertrichosis, exacerbation of underlying symptoms

General Disorders and Administration Site Conditions

Very rare Application site irritation/pain

*Skin features secondary to local and/or systemic effects of hypothalamic-pituitary adrenal (HPA) axis suppression.

Eye disorders

Not known Vision, blurred (see also *Warnings and Precautions*)

OVERDOSAGE

Symptoms and signs

Topically applied betamethasone valerate may be absorbed in sufficient amounts to produce systemic effects. Acute overdose is very unlikely to occur, however, In the case of chronic overdose or misuse, the features of hypercortisolism may occur (see *Adverse Reactions*).

Treatment

In the event of overdose, betamethasone valerate should be withdrawn gradually by reducing the frequency of application, or by substituting a less potent corticosteroid because of the risk of glucocorticosteroid insufficiency. Further management should be as clinically indicated.

Pharmacological properties

Pharmacodynamic properties

ATC code

D07AC Corticosteroids, potent (group III)

Mechanism of action

Topical corticosteroids act as anti-inflammatory agents via multiple mechanisms to inhibit late phase allergic reactions including decreasing the density of mast cells, decreasing chemotaxis and activation of eosinophils, decreasing cytokine production by lymphocytes, monocytes, mast cells and eosinophils, and inhibiting the metabolism of arachidonic acid.

Pharmacodynamic effects

Topical corticosteroids have anti-inflammatory, antipruritic, and vasoconstrictive properties.

Pharmacokinetic properties**Absorption**

Topical corticosteroids can be systemically absorbed from intact healthy skin. The extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the vehicle and the integrity of the epidermal barrier. Occlusion, inflammation and/or other disease processes in the skin may also increase percutaneous absorption.

Distribution

The use of pharmacodynamic endpoints for assessing the systemic exposure of topical corticosteroids is necessary because circulating levels are well below the level of detection.

Metabolism

Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. They are metabolised, primarily in the liver.

Elimination

Topical corticosteroids are excreted by the kidneys. In addition, some corticosteroids and their metabolites are also excreted in the bile.

Preclinical safety data**Reproductive toxicity**

Subcutaneous administration of betamethasone valerate to mice or rats at doses ≥ 0.1 mg/kg/day or rabbits at doses ≥ 12 micrograms/kg/day during pregnancy produced foetal abnormalities including cleft palate and intrauterine growth retardation.

The effect on fertility of betamethasone valerate has not been evaluated in animals.

Incompatibilities

None known

Shelf-life

The expiry date is indicated on the packaging.

Special precaution for storage

Please refer to the outer packaging

Instructions for Use/Handling

Keep container tightly closed when not in use. Contents are flammable. Keep away from fire, flame or heat. Do not leave Betnovate Scalp Application in direct sunlight.

Version no: HK092021(GDS09/eMCSPC20191022)

Trade marks are owned by or licensed to the GSK group of companies

©2021 GSK group of companies or its licensor

Package Leaflet: Information for the User

Betnovate Scalp Application betamethasone valerate

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet:

1. What Betnovate is and what it is used for
2. What you need to know before you use Betnovate
3. How to use Betnovate
4. Possible side effects
5. How to store Betnovate
6. Contents of the pack and other information

1. What Betnovate is and what it is used for

Betnovate Scalp Application (called 'Betnovate' in this leaflet) contains a medicine called betamethasone valerate. It belongs to a group of medicines called steroids that help to reduce swelling and irritation.

Betnovate is used to help reduce the redness and itchiness of certain scalp problems, such as psoriasis and dermatitis.

2. What you need to know before you use Betnovate

Do not use Betnovate

- if you are allergic (hypersensitive) to betamethasone valerate or any of the other ingredients of Betnovate (listed in Section 6)
- if you have a skin infection on your scalp
- on a child under 1 year.

Do not use Betnovate if any of the above apply to you. If you are not sure, talk to your doctor or pharmacist before using Betnovate.

Warnings and precautions

Talk to your doctor or pharmacist before you use this medicine if:

- you have previously had an allergic reaction with another steroid
- you are applying the liquid under an airtight dressing. These dressings make it easier for the active ingredient to pass through the skin. It is possible to accidentally end up using too much
- you have psoriasis, your doctor will want to see you more often
- you are applying the liquid to broken skin or within the skin folds
- you are applying to a large surface area
- you are applying to thin skin or on children as their skin is thinner than adults and as a result may absorb larger amounts.
- Dressing or bandages should not be used on children where the scalp application is applied.
- Use on children should be limited to 5 days.

Contact your doctor if you experience blurred vision or other visual disturbances.

If you are not sure if any of the above apply to you, talk to your doctor or pharmacist before using this medicine.

Other medicines and Betnovate

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicine, especially if you are taking ritonavir and itraconazole medications.

Pregnancy and breast-feeding and fertility

If you are pregnant or are breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine

3. How to store Betnovate

Always use this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.

Using this medicine

- You usually put Betnovate on your scalp in the morning and at night. This may be reduced as your scalp problem begins to get better.
- Do not use Betnovate more often than prescribed.
- Do not use it for a long time (such as every day for many weeks or months) - unless your doctor tells you to.
- Be very careful not to get the liquid in your eyes. Do not touch your eyes until you have washed your hands.
- If you wash or shampoo your hair it should be dried before applying the liquid.
- If you are applying Betnovate on someone else make sure you wash your hands after use or wear disposable plastic gloves.
- **Do not dry your hair with a hairdryer.**
- **This product is flammable. Keep the liquid away from open fires and flames and all sources of ignition including smoking during application and immediately after use.**

Guidance on how to apply the liquid

1. Wash your hands.
2. Unscrew the bottle cap and place the nozzle on the scalp that needs treating.
3. Gently squeeze the bottle to cover the area with a thin and even layer of liquid.
4. You can rub this liquid in, but you don't have to.
5. Your scalp will feel cool until the liquid has dried.
6. Wash your hands again.
7. It is important not to exceed the prescribed amount.

If you use more Betnovate than you should

If you apply too much or if accidentally swallowed, it could make you ill. Talk to your doctor or go to the hospital as soon as possible.

If you forget to use Betnovate

If you forget to apply Betnovate, apply it as soon as you remember. If it is close to the time you are next meant to apply it you can wait until this time.

If you stop using Betnovate

If you use Betnovate regularly make sure you talk to your doctor before you stop using it as your condition may get worse if stopped suddenly.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Stop using Betnovate and tell your doctor immediately if:

- you find that your skin condition gets worse, you develop a generalised rash or your skin becomes swollen during treatment. You may be allergic to Betnovate, have an infection or need other treatment.
- you have psoriasis and get raised bumps with pus under the skin. This can happen very rarely during or after treatment and is known as pustular psoriasis.

Other side effects you may notice when using Betnovate include:

Common (may affect up to 1 in 10 people)

- a feeling of burning, pain, irritation or itching where the liquid is applied.

Very rare (may affect up to 1 in 10,000 people)

- an increased risk of infection
- an allergic skin reaction where the liquid is applied
- rash, itchy bumpy skin or redness of the skin
- thinning and dryness of your skin and it may also damage or wrinkle more easily
- stretch marks may develop
- veins under the surface of your skin may become more noticeable
- an increase or reduction in hair growth or hair loss and changes in skin colour
- weight gain, rounding of the face
- delayed weight gain or slowing of growth in children
- bones can become thin, weak and break easily
- cloudy lens in the eye (cataract) or increased pressure in eye (glaucoma)
- increased blood sugar levels or sugar in the urine
- high blood pressure

Not Known (frequency cannot be estimated from the available data)

- blurred vision

Reporting of side effects

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.

By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Betnovate

- Keep out of the sight and reach of children.
- Do not use this medicine after the expiry date which is stated on the bottle label or carton after (Exp). The expiry date refers to the last day of that month.
- Store as directed on the packaging
- Keep the container tightly closed when not in use. Contents are flammable. Keep Betnovate Scalp Application away from all sources of fire, flame and heat.
- Do not leave Betnovate Scalp Application in direct sunlight.
- Do not throw away medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Betnovate contains

- The active ingredient is betamethasone valerate. Each 10 ml contains 0.01 ml of betamethasone (0.1 % w/w) as valerate.
- The other ingredients are carbomer, isopropyl alcohol, sodium hydroxide and purified water.

What Betnovate looks like and contents of the pack

Within each carton is a specially designed plastic bottle with a nozzle and cap that contains 100 ml of a sticky liquid.

More Information

If you have any questions or are not sure about anything, ask your doctor or pharmacist who will advise you.

Version number: HK092021(GDS09/UKPIL20191021)

Trade marks are owned by or licensed to the GSK group of companies

© 2021 GSK group of companies or its licensor

包裝單張：使用者須知

禪乃膚 (Betnovate) 頭皮水

betamethasone valerate

在使用本藥物前，請仔細閱讀本單張，因為其中包含重要資訊。

- 請保留本單張。您可能需要再次閱讀。
- 如果您有任何進一步的疑問，請諮詢您的醫生或藥劑師。
- 本藥物為醫生專門為您處方。請勿擅自將本藥物傳給他人。儘管他人的症狀和您一樣，但是還是可能會對他們造成損害。
- 如果您出現了任何副作用，請告知您的醫生或藥劑師。這包括未在本說明書中列出的任何可能的副作用。參見第 4 部分。

本單張包括:

1. 禪乃膚(Betnovate)是什麼及有何用途
2. 在使用禪乃膚(Betnovate)前，您需了解哪些資訊
3. 如何使用禪乃膚(Betnovate)
4. 可能出現的副作用
5. 如何存放禪乃膚(Betnovate)
6. 包裝內容和其他資訊

1. 禪乃膚(Betnovate)是什麼及有何用途

禪乃膚(Betnovate) 頭皮水（本單張中名為‘禪乃膚’）含有一種名為 betamethasone valerate 的藥物。它屬於一種稱為類固醇的藥物，能減輕皮膚刺激並且消腫。

禪乃膚(Betnovate)被用於減輕某些因頭皮問題而引起的發紅和痕癢，例如皮炎和銀屑病（psoriasis）。

2. 在使用禪乃膚(Betnovate)前，您需要了解哪些資訊

如有以下情況，切勿使用禪乃膚(Betnovate)：

- 如果您對betamethasone valerate或本藥物中的任何其他成份有嚴重過敏反應（在第6部分 *包裝內容和其他資訊*中列出）
- 如果您的頭皮上有皮膚感染
- 未滿1歲的兒童

如果任何上述情況適用於您，請勿使用本藥物。如果您有不明白的地方，請在使用禪乃膚 (Betnovate) 前諮詢您的醫生或藥劑師。

警告和注意事項

- 如果您存在如下情況，請在用藥前諮詢您的醫生或藥劑師：
- 您曾對另一種類固醇出現過敏情況。
- 您在不透氣的敷料遮蓋的情況下使用本頭皮水。這些不透氣的敷料會讓本藥物中的活性成份更容易滲透皮膚。有可能會意外地吸收過多藥物。
- 您患有銀屑病（psoriasis），您的醫生將會希望您能多覆診。
- 您在皮膚破損處或皮膚褶皺下使用頭皮水。
- 您將在較大的範圍塗抹頭皮水。
- 您在皮膚較薄處或兒童身上使用，因為他們的皮膚厚度比成年人薄，會因此吸收更多的藥物。
- 如果兒童使用本藥物，不得用敷料或繃帶遮住用藥部位。
- 如果兒童使用本藥物，療程不得超過 5 天

如果您出現視野模糊或其他視覺障礙的情況，請諮詢您的醫生。

如果您無法確定上述任何情況是否適用於您，請在使用本藥物前諮詢您的醫生或藥劑師。

其他藥物與禕乃膚(Betnovate) 如果您正在服用，或近期服用過，或可能會服用任何其他藥物，尤其是如果您正在服用 ritonavir 和 itraconazole 接受治療，請將此告知您的醫生或藥劑師。

懷孕、哺乳和生育

如果您已經懷孕或在哺乳期中，可能懷孕或計劃懷孕，請在使用本藥物前諮詢您的醫生或藥劑師。

3. 如何使用禕乃膚(Betnovate)

務必遵從醫生指示服用。如果您有不明白的地方，請諮詢您的醫生或藥劑師。

使用本藥物

- 一般情況下，您會在早上和晚間在頭皮部位用藥。隨著頭皮情況有所好轉，用藥量可適當減少
- 用藥次數不得超過處方規定
- 不得長期使用本藥物（例如每天使用，連續用藥數周或數月），除非有醫生指示
- 務必小心謹慎，切勿讓頭皮水進入眼睛。如果沒有洗手，切勿用手觸碰眼睛
- 如果您用水或洗髮水洗頭，那麼在使用本藥物前應先擦乾頭髮
- 如果您為他人塗抹本藥物，請確保您在接觸藥物後洗手，或用藥前戴上一一次性手套
- **請勿用吹風機吹乾頭髮**
- **本藥物易燃。在用藥期間以及用藥完成後，立即讓本頭皮水遠離明火和火焰以及所有點火源頭，包括燃點香煙**

用藥指南

1. 清洗雙手。
2. 擰開瓶蓋，將瓶嘴直接對準需要用藥的頭皮區域。
3. 輕輕擠壓瓶身，讓頭皮水均勻及薄薄地覆蓋這一區域。
4. 您可以輕揉頭皮以促進頭皮水吸收，但這不是必需的。
5. 在頭皮水乾透之前，您的頭皮會有涼爽的感覺。
6. 再次清洗雙手。
7. 用藥量不得超過處方規定。

如果您使用了過量的禕乃膚(Betnovate)

如果您使用了過量的禕乃膚(Betnovate)，或不小心中吞服本藥物，您可能會因此產生不適。請立即諮詢您的醫生或前往醫院就醫。

如果您忘記使用禕乃膚(Betnovate)

如果您忘記使用頭皮水，請在記起時立即使用。如果此時接近於下次用藥時間，請等到下次再用藥。

如果您停止使用禕乃膚(Betnovate)

如果您一直在按時使用禕乃膚(Betnovate)，那麼在停止用藥前，請諮詢您的醫生，因為如果您突然停止用藥，您的病情可能會惡化。

如果您對本藥物的使用有任何進一步的疑問，請諮詢您的醫生或藥劑師。

4. 可能出現的副作用

和所有藥物一樣，本藥物也會引發一些副作用，儘管並非所有人都會出現這些症狀。

如果出現以下情況，請停止使用禕乃膚(Betnovate)並立即諮詢您的醫生：

- 發現頭皮問題惡化，出現周身皮疹或在治療期間皮膚腫脹。您可能對本頭皮水過

敏，出現感染或需要接受其他治療。

- 患有銀屑病而且在皮下出現凸起的化膿腫塊。這種非常罕見的情況會出現在治療當中或治療結束之後，這被稱為膿皰性銀屑病（pustular psoriasis）。

您在使用禪乃膚(Betnovate)時可能會注意到的其他副作用：

常見（每 10 個人中最多有 1 人可能會受此影響）

- 用藥處感到灼燒、疼痛、刺激或痕癢

極為罕見（每 10,000 個人中最多有 1 人可能會受此影響）

- 增加感染的機會
- 用藥處出現過敏反應
- 皮疹，皮膚痕癢腫脹，發紅
- 皮膚變薄或乾燥，而且可能更容易受損或起皺
- 皮膚可能會出現伸展紋
- 皮下血管會變得更加清晰可見
- 增加或減少頭髮生長，脫髮和膚色改變
- 體重增加，面部變圓
- 兒童體重增加緩慢或生長發育緩慢
- 骨骼變得脆弱，並更容易骨折
- 晶狀體渾濁（白內障）或眼壓增高（青光眼）
- 血糖或尿糖升高
- 高血壓

未知（根據現有數據未能估計副作用出現頻率）

- 視力模糊

報告副作用

如果您出現了任何副作用，請告知您的醫生或藥劑師。這包括未在本手冊中列出的任何可能的副作用。透過報告副作用，您能幫助提供更多有關此藥物安全性的資料。

5. 如何存放禪乃膚 (Betnovate)

- 請將本藥物放在兒童無法看見並觸及的地方。
- 如果本藥物放置超過了藥瓶和包裝盒上印制的有效期，切勿使用。
- 請按照外包裝上的說明進行存放。
- 不使用時，請保持容器密封。容器盛有易燃物品。讓本藥物遠離所有明火、火焰和熱量來源。
- 切勿將藥物置於陽光直射的環境中。
- 請勿將藥物當一般家居廢物或直接經排污系統丟棄。請向您的藥劑師查詢如何丟棄不用的藥物。這將幫助保護環境。

6. 包裝內容和其他資訊裨乃膚(Betnovate)含有哪些成份

- 活性成分為 betamethasone valerate。每 10 毫升頭皮水含有 0.01 毫升 betamethasone (0.1% w/w) as valerate。
- 其他成分有 carbomer、isopropyl alcohol、sodium hydroxide 和 purified water。

裨乃膚(Betnovate)的外觀和包裝內容

每個包裝盒內有一個特別設計的、帶有瓶嘴和瓶蓋的塑膠瓶，其中裝有粘性藥液。

更多諮詢

如果您有任何疑問或有不明白的地方，請諮詢您的醫生或藥劑師，他們會給您建議。

版本編號：HK092021(GDS09/UKPIL20191021)

商標為葛蘭素史克集團擁有或經授權使用。

©2021 葛蘭素史克集團或其授權人。